Summary
Based on encouragingin vitro andin vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1–5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1–5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.
Similar content being viewed by others
References
Boring CC, Squires TS, Tong T. Cancer Statistics, 1992. Ca 42:19–38, 1992
Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967–1972, 1992
Von Hoff DD.In vitro data supporting interferon plus cytotoxic agent combinations. 18:58–61, 1991
Krigel RL, Slywotzky CM, Lonberg M, Green MD, Andes WA, Kempf R, Gupta S, Grace W, Spiegel RJ, Muggia FM, Grossberg H. Treatment of epidemic Kaposi's sarcoma with a combination of interferon-alpha-2b and etoposide. J Biol Resp Modif 7:359–364, 1988
Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for therapy-induced toxicity. Cancer Invest 8:141–153, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ajani, J.A., Abbruzzese, J.L., Markowitz, A.B. et al. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs 11, 67–69 (1993). https://doi.org/10.1007/BF00873914
Issue Date:
DOI: https://doi.org/10.1007/BF00873914